The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients

Tolvaptan, a selective vasopressin V2 receptor antagonist, is the first and only approved specific treatment for Autosomal-Dominant Polycystic Kidney Disease (ADPKD), and is used in current clinical practice. Real clinical data are missing. In this retrospective study, 41 ADPKD patients received tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkika, Vasiliki, Louka, Michaela, Tsagkatakis, Mihail, Tsirpanlis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514807/
https://www.ncbi.nlm.nih.gov/pubmed/37736928
http://dx.doi.org/10.3390/clinpract13050092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514807/
https://www.ncbi.nlm.nih.gov/pubmed/37736928
http://dx.doi.org/10.3390/clinpract13050092

Ejemplares similares